HealthBeacon SHA

Earnings Release • Feb 10, 2022

National Storage Mechanism | Additional information

RNS Number : 3398B

HealthBeacon PLC

10 February 2022

10 February 2022

HealthBeacon adds five further pharmaceutical and national healthcare systems to its client base

HealthBeacon plc ("HealthBeacon" or the "Company"), the leading digital therapeutics company that develops products for managing injectable medications for patients in the home, is pleased to announce it has added a further five clients to date in 2022, in addition to its 18 clients at the time of IPO in December 2021.

The new clients include three pharmaceutical companies and two programmes through the UK's National Health Service (NHS) and the Irish Health Service Executive (HSE). These additions will further strengthen the Company's customer base which now includes Amryt, Novartis, NHS, HSE, Sanofi, Accord Healthcare, Clonmel Healthcare, Teva, Viatris, and AbbVie. The Company remains focused on expanding its client base within Pharmaceutical Companies, Specialty Pharmacy, Healthcare Organisations and Governments and deepening its existing relationships.

These new agreements and continued rollout of its technology and services through pharmaceutical companies and governments underpins HealthBeacon's target of 100,000 units by the end of 2023 and the potential for further significant growth in the medium term.

Jim Joyce, CEO, and co-founder of HealthBeacon commented:

"These new client wins add to the very significant momentum in the business as leading pharma companies and health systems adopt our technology.  We are pleased to be working with some of the most high-profile and innovative global health organisations across our key markets.

The Company's leading injectable medication management platform alongside its highly innovative patient services technology platform give us leadership in all markets we serve. Unfortunately, one in two patients on chronic and critical self-administered injectable medications fail to initiate treatment or discontinue therapy within the first 12 months. HealthBeacon's technology and services supports those patients and enhances their likelihood of success on these important medications, something that is increasingly recognised by many of the world's largest healthcare organisations"

Enquiries:
HealthBeacon: Laurence Flavin	Investor.Relations@HealthBeacon.com
Goodbody (Euronext Growth Adviser and Broker): David Kearney	+353 (1) 667 0420
Stephen Kane
Drury (Public Relations):
Billy Murphy	+353 (0) 87 231 3085
Cathal Barry	+353 (0) 87 227 9281

Ends

About HealthBeacon

Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops products for managing injectable medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. The Company operates in 17 countries primarily across Europe, North America and the United Kingdom employs more than 50 people and has obtained more than 30 design and utility patents. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients, which improves clinical outcomes and significantly improves efficiency in health systems. The Company's mission is to become the world's leading digital therapeutics platform for injectable medications. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEBSGDDDGBDGDG